Crescent Biopharma, Inc.CBIONASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+202.6%
5Y CAGR+70.4%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+202.6%/yr
Quarterly compound
5Y CAGR
+70.4%/yr
Recent acceleration
Percentile
P97
Near historical high
vs 5Y Ago
14.4x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 226.76% |
| Q3 2025 | 20.92% |
| Q2 2025 | -334.02% |
| Q1 2025 | -37.94% |
| Q4 2024 | -119.08% |
| Q3 2024 | 318.16% |
| Q2 2024 | 15.37% |
| Q1 2024 | -38.00% |
| Q4 2023 | 12.30% |
| Q3 2023 | -24.49% |
| Q2 2023 | 39.91% |
| Q1 2023 | -46.71% |
| Q4 2022 | 8.19% |
| Q3 2022 | 46.91% |
| Q2 2022 | -18.49% |
| Q1 2022 | -6.96% |
| Q4 2021 | 24.43% |
| Q3 2021 | -24.50% |
| Q2 2021 | 3.64% |
| Q1 2021 | -45.83% |
| Q4 2020 | 15.80% |
| Q3 2020 | 20.95% |
| Q2 2020 | -315.75% |
| Q1 2020 | 72.64% |
| Q4 2019 | 4.88% |
| Q3 2019 | -18.03% |
| Q2 2019 | 20.58% |
| Q1 2019 | -43.76% |
| Q4 2018 | 1.03% |
| Q3 2018 | 22.77% |
| Q2 2018 | -27.91% |
| Q1 2018 | -21.99% |
| Q4 2017 | -34.33% |
| Q3 2017 | -2.00% |
| Q2 2017 | 32.59% |
| Q1 2017 | -52.18% |
| Q4 2016 | 20.31% |
| Q3 2016 | -5.61% |
| Q2 2016 | 23.35% |
| Q1 2016 | -32.66% |